Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 352Neoplasm Metastasis 31Stomach Neoplasms 30HER2-positive Breast Cancer 19Neoplasms 16Breast Neoplasms, Male 16Brain Neoplasms 13Inflammatory Breast Neoplasms 12Esophageal Neoplasms 10Colorectal Neoplasms 10Triple Negative Breast Neoplasms 8Adenocarcinoma 7Prostatic Neoplasms 6Cardiotoxicity 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 5Lung Neoplasms 5Carcinoma, Ductal, Breast 5Biliary Tract Neoplasms 5Salivary Gland Neoplasms 4Pathologic Complete Response 4Pancreatic Neoplasms 4Meningeal Neoplasms 4Colonic Neoplasms 4Breast Diseases 4Recurrence 3Rectal Neoplasms 3Meningeal Carcinomatosis 3Gallbladder Neoplasms 3Carcinoma, Lobular 3

Interventions

Nivolumab 2pembrolizumab 1folfirinox 1durvalumab 1Trastuzumab 1Single Person 1Paclitaxel 1Irinotecan 1IFL protocol 1Folfox protocol 1Docetaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gastroesophageal Adenocarcinoma × Trastuzumab × Clear all
NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

University of California, Irvine

Phase 1 Recruiting
20 enrolled
Gastrointestinal

Gastroesophageal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡